The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

Chaitra Ujjani; Anthony R. Mato; Brian T. Hill; John N. Allan; Frederick Lansigan; Ryan Jacobs; Alan Skarbnik; Hande H. Tuncer; John M. Pagel; Danielle Brander; Bruce D. Cheson; Paul M. Barr; Lindsey E. Roeker; Jeffrey J. Pu; Nirav N. Shah; Andre Goy; Stephen J. Schuster; Nicole Lamanna; Alison R. Sehgal; Constantine Tam; Mazyar Shadman

doi:10.2147/BLCTT.S262592

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

Chaitra Ujjani, Anthony R. Mato, Brian T. Hill, John N. Allan, Frederick Lansigan, Ryan Jacobs, Alan Skarbnik, Hande H. Tuncer, John M. Pagel, Danielle Brander, Bruce D. Cheson, Paul M. Barr, Lindsey E. Roeker, Jeffrey J. Pu, Nirav N. Shah, Andre Goy, Stephen J. Schuster, Nicole Lamanna, Alison R. Sehgal, Constantine TamMazyar Shadman

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.

Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib was associated with a greater mortality in older patients outside of a clinical trial setting. This multicenter analysis was performed by investigators at 20 academic and community practices.

Results: Amongst the 391 patients included, there was no correlation between age and response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients >65-years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).

Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.

Original language	English
Number of pages	5
Journal	Blood and Lymphatic Cancer: Targets and Therapy
Volume	10
DOIs	https://doi.org/10.2147/BLCTT.S262592
Publication status	Published - 2020
Externally published	Yes

Access to Document

10.2147/BLCTT.S262592Licence: CC BY-NC

Cite this

Ujjani, C., Mato, A. R., Hill, B. T., Allan, J. N., Lansigan, F., Jacobs, R., Skarbnik, A., Tuncer, H. H., Pagel, J. M., Brander, D., Cheson, B. D., Barr, P. M., Roeker, L. E., Pu, J. J., Shah, N. N., Goy, A., Schuster, S. J., Lamanna, N., Sehgal, A. R., ... Shadman, M. (2020). The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. Blood and Lymphatic Cancer: Targets and Therapy, 10. https://doi.org/10.2147/BLCTT.S262592

@article{78f5cc23dd3c4525ad41ed035db1ae80,

title = "The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy",

abstract = "Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib was associated with a greater mortality in older patients outside of a clinical trial setting. This multicenter analysis was performed by investigators at 20 academic and community practices.Results: Amongst the 391 patients included, there was no correlation between age and response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients >65-years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.",

author = "Chaitra Ujjani and Mato, {Anthony R.} and Hill, {Brian T.} and Allan, {John N.} and Frederick Lansigan and Ryan Jacobs and Alan Skarbnik and Tuncer, {Hande H.} and Pagel, {John M.} and Danielle Brander and Cheson, {Bruce D.} and Barr, {Paul M.} and Roeker, {Lindsey E.} and Pu, {Jeffrey J.} and Shah, {Nirav N.} and Andre Goy and Schuster, {Stephen J.} and Nicole Lamanna and Sehgal, {Alison R.} and Constantine Tam and Mazyar Shadman",

year = "2020",

doi = "10.2147/BLCTT.S262592",

language = "English",

volume = "10",

journal = "Blood and Lymphatic Cancer: Targets and Therapy",

issn = "1179-9889",

publisher = "Dove Medical Press Ltd.",

}

Ujjani, C, Mato, AR, Hill, BT, Allan, JN, Lansigan, F, Jacobs, R, Skarbnik, A, Tuncer, HH, Pagel, JM, Brander, D, Cheson, BD, Barr, PM, Roeker, LE, Pu, JJ, Shah, NN, Goy, A, Schuster, SJ, Lamanna, N, Sehgal, AR, Tam, C & Shadman, M 2020, 'The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy', Blood and Lymphatic Cancer: Targets and Therapy, vol. 10. https://doi.org/10.2147/BLCTT.S262592

TY - JOUR

T1 - The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

AU - Ujjani, Chaitra

AU - Mato, Anthony R.

AU - Hill, Brian T.

AU - Allan, John N.

AU - Lansigan, Frederick

AU - Jacobs, Ryan

AU - Skarbnik, Alan

AU - Tuncer, Hande H.

AU - Pagel, John M.

AU - Brander, Danielle

AU - Cheson, Bruce D.

AU - Barr, Paul M.

AU - Roeker, Lindsey E.

AU - Pu, Jeffrey J.

AU - Shah, Nirav N.

AU - Goy, Andre

AU - Schuster, Stephen J.

AU - Lamanna, Nicole

AU - Sehgal, Alison R.

AU - Tam, Constantine

AU - Shadman, Mazyar

PY - 2020

Y1 - 2020

N2 - Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib was associated with a greater mortality in older patients outside of a clinical trial setting. This multicenter analysis was performed by investigators at 20 academic and community practices.Results: Amongst the 391 patients included, there was no correlation between age and response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients >65-years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.

AB - Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib was associated with a greater mortality in older patients outside of a clinical trial setting. This multicenter analysis was performed by investigators at 20 academic and community practices.Results: Amongst the 391 patients included, there was no correlation between age and response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients >65-years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.

U2 - 10.2147/BLCTT.S262592

DO - 10.2147/BLCTT.S262592

M3 - Article

C2 - 32943973

SN - 1179-9889

VL - 10

JO - Blood and Lymphatic Cancer: Targets and Therapy

JF - Blood and Lymphatic Cancer: Targets and Therapy

ER -